Last reviewed 2026-04-22 · How we verify

AK102

AK102 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.

AK102 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).

At a glance

Mechanism of action

AK102 functions as a bispecific monoclonal antibody designed to bind both PD-1 and CTLA-4, two key immune checkpoint molecules. By engaging both pathways simultaneously, it aims to provide superior T-cell activation and anti-tumor immunity compared to single-checkpoint inhibitors. This dual mechanism is intended to overcome resistance to monotherapy and improve clinical outcomes in solid tumors.

Approved indications

• Advanced or metastatic solid tumors (Phase 3 development)

Common side effects

• Immune-related adverse events (irAEs)
• Fatigue
• Diarrhea
• Rash

Key clinical trials

• A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia (PHASE3)
• A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia (PHASE3)
• A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia (PHASE3)
• A Study of PCSK9 Inhibitor AK102 in Healthy Subjects (PHASE1)
• A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH (PHASE2)
• A Long-term Study of AK102 in Patients With Hypercholesterolemia (PHASE2)
• A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) (PHASE2)
• A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.